-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $50

Benzinga·08/04/2026 17:40:26
語音播報
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $45 to $50.